1 / 5

Cancer Monoclonal Antibodies Market Size, Growth and Forecast to 2029

Cancer Monoclonal Antibodies Market size was valued at USD 47.2 billion and is expected to grow at a CAGR of 11.8% during 2023-2029. A monoclonal antibody drug in cancer treatments engages natural immune system functions to fight cancer. Cancer monoclonal antibodies may be used in combination with other cancer treatments. An antibody attaches itself to a specific molecule (antigen) on the surface of a cancer cell when the antibody binds to an antigen, it acts as a flag to attract disease-fighting molecules or as a trigger that promotes the destruction of cancer cells by another immune system p

shristis030
Download Presentation

Cancer Monoclonal Antibodies Market Size, Growth and Forecast to 2029

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Cancer Monoclonal Antibodies Market (2023-29)

  2. Market Overview: Cancer Monoclonal Antibodies Market size was valued at USD 47.2 billion and is expected to grow at a CAGR of 11.8% during 2023-2029. The cancer monoclonal antibodies market research report also provides opportunities for business owners to exploit through the use of relevant approaches. The study’s prospects assist stakeholders and report purchasers in properly planning their investments and augmenting their profits. The report provides a quantitative analysis of the market segments, trends, estimations, and dynamics of thecancer monoclonal antibodies market analysis from 2023 to 2029 to identify the prevailing market opportunities. In addition, the report discusses the implications of COVID-19, including the industry's initial response and strategies for ensuring business continuity in the coming years. View Detailed Report Description

  3. Market Segments: The cancer monoclonal antibodies market has been fragmented based on: 1) By Application: Breast Cancer, Blood Cancer, Liver Cancer, Brain cancer, Colorectal Cancer, Other 2) By Type of Antibody: Murine Antibodies, Humanized Antibodies, Chimeric Antibodies 3) By Conjugation: Immunocytokines, Immunoliposome, Radioimmunotherapy, Antibody Directed Enzyme Prodrug Therapy (ADEPT) 4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies. Request Sample Report

  4. Key Players: • Some of the major key players in the cancer monoclonal antibodies market are: • Merck & Co. Inc. (U.S.) • F. Hoffmann-La Roche AG (Switzerland) • Spectrum Pharmaceuticals (U.S.) • Eli Lilly and Company (U.S.) • Amgen Inc. (U.S.) • Bristol-Meyer Squibb (U.S.) • Sanofi (France) • AstraZeneca (U.K.) • Request Sample Report

  5. Europe Office: Precision Business Insights, Kemp House, 152 – 160 City Road, London EC1V 2NX Asia-Pacific Office: Precision Business Insights, MIG 366, SAI PLAZA, 1st Floor, KPHB Colony, Hyderabad – 500072 Email: sales@precisionbusinessinsights.com Toll-Free: +1-866-598-1553

More Related